or Try an Advanced Search...

    Technical Analysis for CMRX - Chimerix, Inc.

    Grade Last Price % Change Price Change
    F 0.89 -1.66% -0.02
    CMRX closed down 1.66 percent on Thursday, April 25, 2024, on 58 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 1
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical CMRX trend table...
    Date Alert Name Type % Chg
    Outside Day Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction -1.66%
    Inside Day Range Contraction -1.66%
    Oversold Stochastic Weakness -1.66%
    Oversold Stochastic Weakness -3.71%
    Lower Bollinger Band Walk Weakness -2.51%
    Oversold Stochastic Weakness -2.51%
    New 52 Week Closing Low Bearish 0.75%
    180 Bearish Setup Bearish Swing Setup 0.75%
    Older End-of-Day Signals for CMRX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 16 hours ago
    Down 2 % about 16 hours ago
    Rose Above Previous Day's High about 22 hours ago
    10 DMA Resistance about 22 hours ago
    Outside Day about 22 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CMRX Chart by TradingView
    Basic chart:

    Profile

    Chimerix, Inc. Description

    Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox. The company also develops CMX157, an oral nucleotide compound that is in Phase I clinical trials to treat HIV infections. It has a collaboration and license agreement with Merck, Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Viruses Virus Antiviral Drug Hematopoietic Stem Cell Herpes Papillomavirus Ebola Monkeypox Prodrugs Poxviruses Antivirals Cytomegalovirus Infection Orthopoxvirus

    Is CMRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
    Apr 16 Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Apr 15 We Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth Carefully
    Mar 21 Chimerix Appoints Marc D. Kozin to Board of Directors
    Mar 5 Chimerix Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
    Mar 1 Chimerix: Tackling A Strong Unmet Need With Promising Data
    Mar 1 Chimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Call Transcript
    Mar 1 Q4 2023 Chimerix Inc Earnings Call
    Feb 29 Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript
    Feb 29 Chimerix files for $250M mixed shelf offering
    See more CMRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.57
    52 Week Low 0.88
    Average Volume 417,327
    200-Day Moving Average 1.02
    50-Day Moving Average 1.07
    20-Day Moving Average 0.97
    10-Day Moving Average 0.92
    Average True Range 0.06
    RSI (14) 36.71
    ADX 29.38
    +DI 9.68
    -DI 21.45
    Chandelier Exit (Long, 3 ATRs) 0.92
    Chandelier Exit (Short, 3 ATRs) 1.05
    Upper Bollinger Bands 1.08
    Lower Bollinger Band 0.85
    Percent B (%b) 0.17
    BandWidth 23.78
    MACD Line -0.04
    MACD Signal Line -0.04
    MACD Histogram -0.003
    Fundamentals Value
    Market Cap 79.2 Million
    Num Shares 88.9 Million
    EPS -0.96
    Price-to-Earnings (P/E) Ratio -0.93
    Price-to-Sales 72.90
    Price-to-Book 0.40
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.98
    Resistance 3 (R3) 0.99 0.96 0.96
    Resistance 2 (R2) 0.96 0.94 0.96 0.96
    Resistance 1 (R1) 0.93 0.93 0.92 0.92 0.95
    Pivot Point 0.90 0.90 0.90 0.90 0.90
    Support 1 (S1) 0.87 0.88 0.86 0.86 0.83
    Support 2 (S2) 0.85 0.87 0.84 0.82
    Support 3 (S3) 0.81 0.85 0.82
    Support 4 (S4) 0.80